VYNE Therapeutics (VYNE) MST Sale is Good news, Underscores Company's Ability to Execute - Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $10.00 price target on VYNE Therapeutics (NASDAQ: VYNE), following announcement ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
